ORBIMED ADVISORS LLC is an investment firm that reports beneficial ownership of shares in BlossomHill Therapeutics, Inc. (BLSM) and 21 other companies under U.S. securities law. It has submitted 55 SEC insider filings since 2024, most recently in August 2026.
Every role ORBIMED ADVISORS LLC has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
BlossomHill Therapeutics, Inc. (BLSM)1 filingBraveheart Bio, Inc. (BRVE)1 filingScribe Therapeutics, Inc. (SCTX)1 filingSionna Therapeutics, Inc. (SION)2 filingsEnliven Therapeutics, Inc. (ELVN)2 filingsShattuck Labs, Inc. (STTK)2 filingsQ32 Bio Inc. (QTTB)1 filingUpdated Aug 30, 2026
ORBIMED ADVISORS LLC is Director of BlossomHill Therapeutics, Inc. (BLSM). 42 SEC Form 4 filings on record going back to 2024, most recently on 12 August 2026. Most recent open-market trade: bought $10.00M of BLSM on 12 August 2026. Lifetime open-market purchases: $122.92M. Lifetime open-market sales: $154.99M. Historical track record: 4/5 stars across 11 tracked purchases.
Every recent SEC Form 4 transaction ORBIMED ADVISORS LLC has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★★☆ (4/5) |
| Total purchases tracked | 11 |
| Purchases with forward-return data | 11 |
| 30-day win rate | 64% |
| 90-day win rate | 18% |
| Avg 5-day return | +0.92% |
| Avg 30-day return | +28.43% |
| Avg 90-day return | -5.11% |
| Best 30-day return |
InsiderAlpha's records for ORBIMED ADVISORS LLC go back to 2024: 42 primary Form 4 filings, an average of 14.0 per year. The typical open-market purchase is $4.39M (28 buys totaling $122.92M). The largest single buy on record is $30.00M of BRVE in 2026. Sales side: 53 recorded sales totaling $154.99M, so the filing history runs sell-heavy by dollar value. 20 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies ORBIMED ADVISORS LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
ORBIMED ADVISORS LLC is an investment firm, tracked as Director of BlossomHill Therapeutics, Inc. (BLSM). InsiderAlpha holds 42 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
10 primary Form 4 filings in the last 90 days, covering 7 companies.
Recorded transactions: 28 open-market purchases ($122.92M) and 53 open-market sales ($154.99M) across all tracked filings.
Across 11 tracked purchases, ORBIMED ADVISORS LLC averaged +28.4% avg 30-day return with a 64% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$BLSM BlossomHill Therapeutics, Inc.1.04M shares @ --
| +136.49% |